AZD7986

• CAT Number: I003827
• CAS Number: 1802148-05-5
• Molecular Formula: C23H24N4O4
• Molecular Weight: 420.47
• Purity: ≥95%
• Synonyms: AZD7986; AZD-7986; AZD 7986; INS 1007; INS-1007; INS1007.;(S)-N-((S)-1-cyano-2-(4-(3-methyl-2-oxo-2,3-dihydrobenzo[d]oxazol-5-yl)phenyl)ethyl)-1,4-oxazepane-2-carboxamide
• Target: DPPI inhibitor
• Solubility: Soluble in DMSO
• Storage: Store at -20°C
• IUPAC Name: (2S)-N-[(1S)-1-cyano-2-[4-(3-methyl-2-oxo-1,3-benzoxazol-5-yl)phenyl]ethyl]-1,4-oxazepane-2-carboxamide
• InChI: InChI=1S/C23H24N4O4/c1-27-19-12-17(7-8-20(19)31-23(27)29)16-5-3-15(4-6-16)11-18(13-24)26-22(28)21-14-25-9-2-10-30-21/h3-8,12,18,21,25H,2,9-11,14H2,1H3,(H,26,28)/t18-,21-/m0/s1
• InChIKey: AEXFXNFMSAAELR-RXVVDRJESA-N
• SMILES: CN1C2=C(C=CC(=C2)C3=CC=C(C=C3)CC(C#N)NC(=O)C4CNCCCO4)OC1=O

AZD7986（Cat No.:I003827）, or INS 1007, is a second-generation reversible covalent inhibitor that specifically targets dipeptidyl peptidase 1 (DPP1). It is being developed as a potential treatment for chronic obstructive pulmonary disease (COPD). AZD7986 demonstrates potent and selective inhibition of DPP1 activity and has predicted pharmacokinetic (PK) properties that suggest it could be suitable for once-daily dosing in humans. This compound holds promise as a therapeutic option for COPD, although further research and clinical trials are necessary to evaluate its efficacy and safety in humans.

Reference

1:J Med Chem. 2016 Oct 27;59(20):9457-9472. Epub 2016 Oct 11. Discovery of Second Generation Reversible Covalent DPP1 Inhibitors Leading to an Oxazepane Amidoacetonitrile Based Clinical Candidate (AZD7986).Doyle K,Lönn H,Käck H,Van de Poël A,Swallow S,Gardiner P,Connolly S,Root J,Wikell C,Dahl G,Stenvall K,Johannesson P, PMID: 27690432 DOI: 10.1021/acs.jmedchem.6b01127 Abstract: A novel series of second generation DPP1 inhibitors free from aorta binding liabilities found for earlier compound series was discovered. This work culminated in the identification of compound 30 (AZD7986) as a highly potent, reversible, and selective clinical candidate for COPD, with predicted human PK properties suitable for once daily human dosing.